The High BMI Study
The study drug is being developed as a potential new treatment for non-alcoholic fatty liver disease (NAFLD).
NAFLD is a condition in which excess fat is stored in the liver and causes liver damage and other serious health complications. It is the most common liver disease in the world.
This study drug is an inhibitor of stearoyl-CoA desaturase 1 (SCD-1), which controls the production of fats in the liver. It was originally developed as an acne treatment, but when applied topically on the skin, studies showed that it lowered the body fat and liver fat metabolism. The study drug is administered in the form of a topical gel, which is applied either on the face or thigh.
The trial has been approved by an independent ethics committee and eligible participants will be reimbursed for their time.
Call us on 1800 243 733 to discuss your eligibility today!